Sign in
SuspendedNo phase

The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults

Key facts

Who runs it
Icahn School of Medicine at Mount Sinai
Where
New York, United StatesSee the site
Trial code
Status
Suspended
People taking part
40 people, planned
Started
26 Aug 2014
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 40 IU Intranasal Oxytocin
  • Placebo
  • 24 IU intranasal Oxytocin
Record updated
2 July 2026
Why it stopped
Study was halted during COVID pandemic. However, PI is currently reconnecting with a compounding pharmacy to re-establish supply of the oxytocin and updating cost estimates. We are hoping to resume the pilot work with oxytocin once it is clarified.

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • BPD subjects meets criteria for DSM-IV Borderline Personality Disorder
  • 18 to 55 years old
  • Healthy controls are free of any lifetime DSM-IV Axis I or Axis II diagnosis. However, to avoid a group of HC's too highly groomed and unrepresentative of the general population subjects meeting criteria for a past Axis I diagnosis of adjustment, dysthymic, or depressive NOS disorders, specific phobias, and sleep disorders will not be excluded. Subjects will not be excluded for a non-IV substance abuse disorder more than 6 months prior to enrollment
  • All subjects will be free of psychotropic medications for 2 weeks (6 weeks for fluoxetine)
  • Subjects may be enrolled in psychotherapy

Who cannot take part

  • Substance abuse disorder in the prior 6 months
  • BPD subjects not meeting DSM-IV criteria for past or present bipolar I disorder, schizophrenia, schizoaffective disorder, substance dependence, head trauma, CNS neurological disease, seizure disorder or current major depression. Since depression is commonly associated with BPD, too stringent a depression exclusion criterion would yield a clinically atypical BPD sample. For this reason, BPD patients with Axis I depressive disorders other than major depression and those with a past history of major depression will not be excluded
  • Significant medical illness
  • Pregnancy
  • Metallic foreign-bodies that contraindicate MRI

Where in United States

  • Icahn School of Medicine at Mount SinaiNew York, United States

About the trial

What the trial wants to find out

The study will examine behavioral patterns and underlying neural correlates which distinguish patients with borderline personality disorder (BPD) from healthy subjects as they participate in a two-person trust game and will determine whether administration of intranasal oxytocin (OT) will normalize trust game performance and concomitant neural processing in the BPD group.

The 2 groups in the trial

  • patients with BPDOther group

    cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo

    Treatment: 40 IU Intranasal Oxytocin, Placebo, and 24 IU intranasal Oxytocin

  • healthy patientsExisting treatment, for comparison

    Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo

    Treatment: 40 IU Intranasal Oxytocin, Placebo, and 24 IU intranasal Oxytocin

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults: A Pilot Behavioral Study
Record updated
2 July 2026
The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults (NCT02225600) – Frontlight Research